Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients

Mantasha Tabassum(University of Houston), Meghana V. Trivedi(University of Houston), Soumya Chikermane(University of Houston), Noor Mazin Abdulkareem(The University of Texas MD Anderson Cancer Center), Michael L. Johnson(University of Houston), E. Wang(University of Houston), Camille S. Johnson(University of Houston)

Cardio-Oncology

March 26, 2024

10.1186/s40959-024-00217-1

Cited by 2

Related Papers

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II

|Value in Health|2009|309

Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer

|Clinical Cancer Research|2013|273

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

|Cancer Research|2018|221

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

|Breast Care|2013|200

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

|Proceedings of the National Academy of Sciences|2016|185